Lineage Cell Therapeutics (LCTX) Revenue (2010 - 2026)

Lineage Cell Therapeutics' Revenue history runs 17 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Revenue rose 14.85% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $14.8 million, a 54.64% increase from a year earlier, with the FY2025 full-year figure at $14.6 million, up 53.24% from the prior year.
• Revenue declined to $1.7 million in Q1 2026 per LCTX's latest filing, from $6.6 million in the prior quarter.
• Across five years, Revenue topped out at $6.6 million in Q4 2025 and bottomed at $1.2 million in Q3 2023.
• The 5-year median for Revenue is $2.8 million (2025), against an average of $2.9 million.
• Biggest YoY gain for Revenue was 1239.39% in 2022; the steepest drop was 96.17% in 2022.
• Year by year, Revenue stood at $1.9 million in 2022, then rose by 9.03% to $2.1 million in 2023, then soared by 37.36% to $2.9 million in 2024, then jumped by 130.4% to $6.6 million in 2025, then sank by 73.9% to $1.7 million in 2026.
• Per Business Quant, the three latest LCTX Revenue figures stand at $1.7 million (Q1 2026), $6.6 million (Q4 2025), and $3.7 million (Q3 2025).